BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 30910457)

  • 1. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
    Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
    Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
    Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
    Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is pathological complete response after a trimodality therapy, a predictive factor of long-term survival in locally-advanced esophageal cancer? Results of a retrospective monocentric study.
    Francoual J; Lebreton G; Bazille C; Galais MP; Dupont B; Alves A; Lubrano J; Morello R; Menahem B
    J Visc Surg; 2018 Oct; 155(5):365-374. PubMed ID: 29501383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.
    Tapias LF; Mathisen DJ; Wright CD; Wain JC; Gaissert HA; Muniappan A; Lanuti M; Donahue DM; Morse CR
    Ann Thorac Surg; 2016 Mar; 101(3):1097-103. PubMed ID: 26652140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma.
    Rice TW; Adelstein DJ; Chidel MA; Rybicki LA; DeCamp MM; Murthy SC; Blackstone EH
    J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1590-6. PubMed ID: 14666038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Disparities After Induction Chemoradiotherapy and Esophagogastrectomy for Esophageal Cancer.
    Rowse PG; Jaroszewski DE; Thomas M; Harold K; Harmsen WS; Shen KR
    Ann Thorac Surg; 2017 Oct; 104(4):1147-1152. PubMed ID: 28842111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
    Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K; Beitler JJ; Shin DM; Willingham FF; El-Rayes B; Landry JC; Fernandez FG; Saba NF
    Cancer; 2017 Sep; 123(18):3476-3485. PubMed ID: 28464264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.
    Shao MS; Wong AT; Schwartz D; Weiner JP; Schreiber D
    Ann Thorac Surg; 2016 Jun; 101(6):2148-54. PubMed ID: 27016842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
    Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
    Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
    Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
    Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
    Fujiwara Y; Yoshikawa R; Kamikonya N; Nakayama T; Kitani K; Tsujie M; Yukawa M; Inoue M; Yamamura T
    Oncol Rep; 2012 Aug; 28(2):446-52. PubMed ID: 22664791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
    Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
    Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
    Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma.
    Yamamoto S; Ishihara R; Motoori M; Kawaguchi Y; Uedo N; Takeuchi Y; Higashino K; Yano M; Nakamura S; Iishi H
    Am J Gastroenterol; 2011 Jun; 106(6):1048-54. PubMed ID: 21343920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.